The hemophilia treatment landscape is to undergo a radical shift away from established short-acting therapies, beginning with the launch of Biogen Idec’s long-acting rFVIII and rFIX products this year, according to research and consulting firm GlobalData.
The GlobalData report states that the patient shares of currently marketed short-acting recombinant products will erode considerably by 2022 across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan).
Brooke Baker, Ph.D., Senior Analyst at GlobalData, says: “Biogen Idec’s new treatments have the potential to reduce the number of weekly prophylactic infusions and greatly improve patients’ convenience and quality of life. By pricing its long-acting agents, namely Eloctate and Alprolix, in line with the established short-acting recombinant factors, [the company] aims to incentivize patients to switch from their previous therapies.”
GlobalData forecasts that peak-year US sales for Eloctate and Alprolix will reach $786 million and $349 million by 2022, respectively.